Cite
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
MLA
Bergman, Martin, et al. “Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.” Rheumatology & Therapy, vol. 9, no. 6, Dec. 2022, pp. 1517–29. EBSCOhost, https://doi.org/10.1007/s40744-022-00483-4.
APA
Bergman, M., Buch, M. H., Tanaka, Y., Citera, G., Bahlas, S., Wong, E., Song, Y., Zueger, P., Ali, M., & Strand, V. (2022). Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Rheumatology & Therapy, 9(6), 1517–1529. https://doi.org/10.1007/s40744-022-00483-4
Chicago
Bergman, Martin, Maya H. Buch, Yoshiya Tanaka, Gustavo Citera, Sami Bahlas, Ernest Wong, Yanna Song, Patrick Zueger, Mira Ali, and Vibeke Strand. 2022. “Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.” Rheumatology & Therapy 9 (6): 1517–29. doi:10.1007/s40744-022-00483-4.